* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Providing Compassionate Care While Avoiding Common Mistakes
National Institute for Health and Care Excellence wikipedia , lookup
Prescription costs wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Neuropharmacology wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Electronic prescribing wikipedia , lookup
Theralizumab wikipedia , lookup
Understanding State Board Regulations: Providing Compassionate Care While Avoiding Common Mistakes Joe Y. Kim, MD Water’s Edge: Memorial’s Pain Relief Institute Washington State • Follows Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain • Federation of State Medical Boards • July 2013 (1997, 2003) Washington State • Since 2004 • 1 in 4 in primary care settings, pain limits ADL’s • Undertreatment of pain is serious public health problem Inappropriate Management • Inadequate initial assessment for clinical indication • Inadequate monitoring • Inadequate attention to patient education/consent • Unjustified dose escalation: risks? alternatives? Discipline • “Physicians should not fear disciplinary action from the Board for ordering, prescribing, dispensing or administering controlled substances, including opioid analgesics, for a legitimate medical purpose and in the course of professional practice, when current best clinical practices are met.” Discipline • “The Board will not take discplinary action against a physician for deviating from this Model Policy when contemporaneous medical records show reasonable cause for such a deviation.” • “The board will judge the validity of the physician’s treatment of a patient on the basis of available documentation, rather than solely on the quantity and duration of medication administered”. Guidelines • Understanding Pain: • Patient Evaluation and Risk Stratification • Development of a Treatment Plan/Goals • Informed Consent/Treatment Agreement Guidelines • Initiating an Opioid Trial • Ongoing Monitoring and Adapting the Treatment Plan • Periodic Drug Testing • Consultation and Referral Guidelines • Discontinuing Opioid Therapy • Medical Records • Compliance with Controlled Substance Laws and Regulations Methadone • Increased rate of methadone related deaths • QTc: pre, 3days, annual • 450-500 ms discuss (debate) • “No evidence has been found to support the use of the EKG for preventing cardiac arrhythmias in methadone-treated opioid dependents” Cochrane investigators Methadone • Follow up sooner after: • • Initiation or increase Pharmacodynamics/kinetics • Analgesic action 6 hrs (morphine is opposite) • Full analgesic effects • • Morphine conversion median 5 days (range 4-13) • May be 1-2 weeks Long half-lfe/accumulation ==> delayed toxicity Methadone • Equianalgesic for repetitive dosing smaller than single-dose • 65 y/o decreased clearance • No liver adjustments • Metabolites do not accumulate with renal failure Methadone • Increased rate of methadone related deaths What is the ideal opioid? • half-life, side effects, metabolites, etc… What is the ideal opioid? Oxycodone No ceiling dose Minimal side effects Absence/minimal activce metabolite Easy titration Rapid onset Short half-life Long duration Predictable pharmacokinetics Random Considerations • T3/T4: ceiling effect 60mg/dose, max 360mg/day • Hyrdocodone: maximal daily 60mg/day? • Morphine: renal failure (M6G); rectal? • Oxymorphone: hepatic impairment Random Considerations • Tapentadol (Nucynta): seizures, ICP, asthma • inhibit serotonin/NE reuptake • Tramadol: 5HT, cardiovascular, seizures, addiction • TCA/MSO4: synergistic CNS/respiratory depression Guidelines • Patient Evaluation and Risk Stratification • • Indication/Evaluation Assessment • Nature, intensity, treatments, comorbidities, function. • ROS, SH, FH (abuse), PE, labs?, SOAPP-R, ORT • All patients should be screened for depression/mental health Guidelines • Assessment • History of substance abuse: failure/harm • • If possible, consult before therapy initiated. Current abuse • Established in treatment/recovery program • Co-managed with addictions specialist Terms • Tolerance • Dependence • Abuse • Addiction Guidelines • Assessment • Brings in own pile of records • • ask for records directly PMP Guidelines • Development of a treatment plan/goals • • • Goals • Improvement of pain and function • Improvement of pain associated symptoms Avoidance of unnecessary/excessive use of meds Revisited regularly Guidelines • Development of a treatment plan/goals • Individualized • Supports selection of treatment • Objectives to evaluate progress • pain relief • physical/psychosocial function Guidelines • • Informed consent • Risks/benefits • Why change Treatment agreement • Goals • Patient’s/physician’s responsibilities Guidelines • Informed consent/Treatment agreement • Shared decision • Store/disposal Guidelines • Initiating an Opioid Trial • Present as a trial (e.g. 90 days) • Evaluate benefit (pain/fxn/QOL) vs. harm • Lowest possible start dose • Short acting Guidelines • Ongoing Monitoring and Adapting the Treatment Plan • Collateral information: family, close contacts, PMP • More frequently at first • Five A’s: Analgesia, Activity, Adverse Effects, Aberrancy, Affect/mood Guidelines • Ongoing Monitoring and Adapting the Treatment Plan • Continue? • Progress towards goals (pain, fxn, QOL) • Absence of risks/adverse events More meds • Psychotherapy • Rehabilitative • Injection • Surgery • Medications More meds • Anti-inflammatory • Antidepressants • Membrane stabilizers • Muscle relaxants • Opioids Escalations • Can be a sign of use disorder/diversion • • Good time to get UDS “halftime” rule High doses • 200mg (MED) in 2010, lower now • Concerns • Hyperalgesia • Neuroendocrine • Immunosuppression Guidelines • Periodic Drug Testing/Screening • Clinical judgement > recommendations • Discuss in supportive fashion • Pill count “useful” • PMP “highly recommended” Opioid Rotation • Intolerable side effects • Inadequate benefit • 25-50% reduction Rotation • Total 24-hour dose • Calculate new dose • 50-65% got incomplete cross-tolerance • Consider rescue Rotation • Fentanyl 50% decrease in 17 hours • Calculate new dose • 50-65% got incomplete cross-tolerance • Consider rescue Guidelines Periodic Drug Testing/Screening • • Unsatisfactory progress • Intervention needed: • early refill • multiple lost/stolen rx • physician shopping • intoxication/impairment • pressuring/threatening behavior • illicit/unprescribed drugs Guidelines • Periodic Drug Testing/Screening • Intervention needed: • Behavior suggesting RECURRING misuse • self-increase dose • deteriorating function • failure to comply to the treatment plan Guidelines • Periodic Drug Testing • “Firm response” • Forgery • Obvious impairment • abusive/assaultive behavior Transit times (inexact) Rapid: • • EtOH 7-12 hrs • Pentobarbitol (24h) • Propoxyphene 6-48 hrs Transit times Fast: • • (Meth) Amphetamine 48 hrs • Codeine 48 hrs • Heroine 48 hrs • Cocaine metabolites 2-4 days • Hydromorphone 2-4 days • Methadone 3 days • Short-acting BZ’s 3days • Long-term/heavy 30 d Transit times Long • • PCP 8 days • Phenobarbital 3 wks • Long-acting BZ’s 30 days Guidelines • Consultation and Referral • • Pain, psychiatry, addiction, or mental health specialist “if needed” • History of substance abuse • Co-occuring mental health disorder Know treatment options in treatment programs for addictions Guidelines Discontinuing Opioid Therapy • • Regularly weigh benefits/risks • Discontinue • resolution • intolerable side effects • inadequate analgesia • failure to improve QOL • significant aberrancy Guidelines • Discontinuing Opioid Therapy • Structured tapering regimen • Withdrawal • • Addiction specialist or physician Not the end (direct care or referral) Weaning off • Repeated aberrant drug-related behaviors • Diversion • Intolerable side effects • No progress towards goals “More Serious” • Repeatedly non adherent • Cocaine • Unprescribed opioids • Doctor Shopping • Unprescribed opioids • Morphine example “Non-serious” • 1-2 unauthorized dose escalations • Alcohol Wean off • Rehabilitation setting ideal • Addiction • Addiction treatment made available • Follow-up • Non-opioid pain management Wean off • Slow: 10%/ week • Rapid: 25-50% every few days • At higher doses, can be more rapid • When get to lower doses, slow down Guidelines • Medical Records • Copies of the signed informed consent and treatment agreement • Patient’s medical history • Results of physical exam and laboratory tests • Results of risk assessment (e.g. screen tools) • Description of treatments provided • Instructions to the patient (e.g. risks, benefits) Guidelines • Medical Records • Results of ongoing monitoring of patient progress (pain/fxn) • Notes on evaluation/consultations of specialists • Any other supporting information to support • Authorization of release of information Universal Precautions • 1. Make a diagnosis with an appropriate differential • 2. Conduct a patient assessment, including risk for substance use disorders • 3. Discuss the proposed treatment plan with the patient and obtain informed consent • 4. Have a written agreement that sets forth the expectations and obligations of both the patient and treating physician • 5. Initiate an appropriate trial of opioid therapy, with or without adjunctive medications Universal Precautions • 6. Perform regular assessments of pain and function. • 7. Reassess the patient’s pain score and level of function • 8. Regularly evaluate the patient in terms of the “5 A’s” • 9. Periodically review the pain diagnosis and any comorbid conditions (including substance use disorders) and adjust the treatement regimen accordingly • 10. Keep careful and complete recored of the initial evaluation and each follow up visit. State Website • Can I drink alcohol while taking pain medication? • • “Talk to your healthcare provider. Alcohol may have unintended consequences…” If a patient has been at 140 mg MED for several years, do I need to consult a pain specialist? • “No, For a patient with stable pain and function, on a non-escalating dosage of opioids, the consultation requirement would not be required as long as the practitioner documents these items.” Scoping the Addict • Most strongly predictive factor: • personal/family history of alcohol/drug abuse. • Younger • Psychiatric history Scoping the Addict • Travel • Escalation of dose • Focus on one medication • Affect • End of week refill The “High Risk Patient” • History of drug abuse • Psychiatric issues • Serious aberrant drug-related behaviors The “High Risk Patient” • Benefits outweigh risks • “Strongly Consider” • Mental health specialist • Addiction specialist The “High Risk Patient” • Referral/change/discontinue • Precise prescription • 4 strikes and you’re out: How often to visit with? • Stable, Low risk: 3-6 months • High risk: up to weekly • addictive disorder • job requiring mental acuity • elderly • social/psychiatric/medical The “High Risk Patient” • Change • More frequent/intense • Tapering (permanent/temporary) • Psychological therapies • Nonopioid treatment The “High Risk Patient” • Discontinue • Diversion, forgery, stealing/buying • Serious aberrant behavior • • Injecting oral meds Dangerous/suicidal behavior Driving • • Effects (Especially at first, with increases, or mixed) • Somnolence • Clouded mentation • Decreased Concentration • Slower reflexes/incoordination Studies don’t show increase accidents Driving • A person is guilty of driving while under the influence of intoxicating liquor or any drug if the person drives a vehicle within this state: While the person is under the influence of or affected by intoxicating liquor or any drug; or While the person is under the combined influence of or affected by intoxicating liquor and any drug. Driving • A person is guilty of negligent driving in the first degree if he or she operates a motor vehicle in a manner that is both negligent and endangers or is likely to endanger any person or property, and exhibits the effects of having consumed liquor or an illegal drug. • However, legal entitlement to use the drug is a defense to the charge of “negligent driving” [§46.61.5249 (1)(a)] if the defendant had a valid prescription for the drug consumed and had been consuming the drug according to the prescription directions and warnings.